NEWARK, Del.--(BUSINESS WIRE)--Strategic Diagnostics Inc. (Nasdaq: SDIX) - a leading provider of biotechnology-based detection solutions for a broad range of life science and industrial applications, today reported financial results for the quarter and year ended December 31, 2008. Revenues for the fourth quarter increased 2% to $7.0 million, compared to $6.9 million for the third quarter of 2008, and decreased 3% compared to $7.3 million in the fourth quarter of 2007. Revenues for the fourth quarter of 2008 were positively impacted by a 260% increase in sales of Genomic Antibody Technology™ (GAT™) products over the comparable prior quarter. The Food Pathogen and Water and Environmental Product business units showed year-over-year declines in revenues of 2% and 22%, respectively, for the quarter. The Ag-GMO business unit showed a 12% increase over the comparable prior quarter.
